title: Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
abstract: From a therapeutic perspective, the bourgeoning literature on Th17 cells should allow us to decide whether to rationally pursue the manipulation of Th17 cells in cancer. The purpose of this review is to attempt a synthesis of a number of contradictory conclusions as to the role that these cells are playing in the process of tumourigenesis in order to provide guidance as to whether our current understanding is sufficient to safely pursue Th17-targeted therapy in cancer at this time. Th17 cells are a highly plastic population and the cytokine drivers for Th17 cell generation and skewing will vary between various cancers and importantly between different sites of tumour involvement in any individual patient. The net impact of the pro-angiogenic IL-17 produced not only by Th17 cells but by other cells particularly macrophages and the anti-tumour effects of Th1/Th17 cells will in turn be determined by the complex interplay of diverse chemokines and cytokines in any tumour microenvironment. Th17 cells that fail to home to tumours may be immunosuppressive. The complexity of IL-17 and Th17 dynamics makes easy prediction of the effects of either enhancing or suppressing Th17 cell differentiation in cancer problematic.
authors.affiliation: Royal Surrey County Hospital, Egerton Road, Guildford, Surrey, GU2 7XX, UK. garymiddleton@nhs.net
authors.forename: Gary W
authors.initials: GW
authors.lastname: Middleton
authors.forename: Nicola E
authors.initials: NE
authors.lastname: Annels
authors.forename: Hardev S
authors.initials: HS
authors.lastname: Pandha
mesh_terms: D002454:Cell Differentiation / Q000276:immunology; D002471:Cell Transformation, Neoplastic / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D058504:Th17 Cells / Q000276:immunology*
references.citation: Nature. 2006 May 11;441(7090):235-8
references.pmid: 16648838
references.citation: Cancer Immunol Immunother. 2011 Dec;60(12):1669-81
references.pmid: 21989580
references.citation: Breast Cancer Res. 2008;10(6):R95
references.pmid: 19014637
references.citation: Eur J Immunol. 2010 Nov;40(11):3017-27
references.pmid: 21061434
references.citation: Blood. 2009 Aug 6;114(6):1141-9
references.pmid: 19470694
references.citation: Immunity. 2009 May;30(5):673-83
references.pmid: 19409816
references.citation: J Immunol. 2005 Jul 1;175(1):404-12
references.pmid: 15972674
references.citation: Blood. 2008 Jul 15;112(2):362-73
references.pmid: 18354038
references.citation: Cancer Res. 2011 Feb 15;71(4):1263-71
references.pmid: 21303976
references.citation: Nat Immunol. 2007 Sep;8(9):942-9
references.pmid: 17676045
references.citation: J Immunol. 2009 Jul 15;183(2):865-73
references.pmid: 19542376
references.citation: Ann Neurol. 2009 Sep;66(3):390-402
references.pmid: 19810097
references.citation: Nat Immunol. 2005 Nov;6(11):1133-41
references.pmid: 16200068
references.citation: Nat Immunol. 2007 Sep;8(9):950-7
references.pmid: 17676044
references.citation: J Immunol. 2002 Feb 15;168(4):1911-8
references.pmid: 11823526
references.citation: Immunity. 2009 Jan 16;30(1):92-107
references.pmid: 19119024
references.citation: Int J Cancer. 2009 Sep 15;125(6):1372-9
references.pmid: 19533748
references.citation: J Immunol. 2011 Mar 15;186(6):3373-82
references.pmid: 21307296
references.citation: Eur J Immunol. 2011 Apr;41(4):936-51
references.pmid: 21381020
references.citation: J Exp Med. 2005 Jan 17;201(2):233-40
references.pmid: 15657292
references.citation: J Hepatol. 2009 May;50(5):980-9
references.pmid: 19329213
references.citation: J Immunol. 2007 Dec 1;179(11):7791-9
references.pmid: 18025225
references.citation: Nature. 2008 Jul 17;454(7202):350-2
references.pmid: 18469800
references.citation: J Immunol. 1995 Dec 15;155(12):5483-6
references.pmid: 7499828
references.citation: Lung Cancer. 2010 Sep;69(3):348-54
references.pmid: 20022135
references.citation: Biochem Biophys Res Commun. 2011 Apr 8;407(2):348-54
references.pmid: 21396350
references.citation: Eur J Immunol. 2008 Jul;38(7):1807-13
references.pmid: 18506885
references.citation: Cancer Immunol Immunother. 2010 Jun;59(6):805-17
references.pmid: 20012860
references.citation: Cancer Immunol Immunother. 2010 Jul;59(7):979-87
references.pmid: 20352428
references.citation: J Immunol. 2005 Nov 1;175(9):6177-89
references.pmid: 16237115
references.citation: Oncol Rep. 2011 May;25(5):1271-7
references.pmid: 21369705
references.citation: J Immunol. 2010 Nov 15;185(10):6348-54
references.pmid: 20952674
references.citation: Nature. 2010 Oct 21;467(7318):967-71
references.pmid: 20962846
references.citation: Nat Immunol. 2005 Nov;6(11):1123-32
references.pmid: 16200070